IL15 and neoplasm: Even though the release of damage-associated signals after NIR-PIT is likely to have been lower in MOC1 cells, IL-15 administration following NIR-PIT nevertheless contributed to enhancement of antitumor host immunity by activating tumor-attacking T and NK cells making this combination therapy similarly effective for all tumors.